Accidental Ixazomib Overdose in a Patient With Multiple Myeloma

Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of oral chemotherapeutic agents for the managemen...

Descripción completa

Detalles Bibliográficos
Autores principales: Sampat, Parth J., Bisen, Maneesh, Srivastava, Nimisha, Rao, Suman, Gentile, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127745/
https://www.ncbi.nlm.nih.gov/pubmed/33980053
http://dx.doi.org/10.1177/23247096211013230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127745/
https://www.ncbi.nlm.nih.gov/pubmed/33980053
http://dx.doi.org/10.1177/23247096211013230

Ejemplares similares